⌕
Scribe Therapeutics · SCTX · Nasdaq
$16.36at last closeTenet — · insufficient data
Compare
$16.36at last close

Scribe Therapeutics (SCTX) Stock

Industry: Biological Products, Except Diagnostic Substances · see every company filed here →

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetHow we compute thisNot investment advice

Scribe Therapeutics, Inc. isn't scored yet Not enough ingested fundamentals to compute a Tenet Score for this stock.

Tenet Score

Not scored. We do not hold normalized financials for this listing, so the Tenet value screens do not apply. That is usually a foreign-domiciled ADR or a very new listing. Its price, chart, and news below are its own.

Price

Loading chart…
P/E
—
no P/E on file
P/B
—
no P/B on file
P/S
—
no P/S on file
ROE
—
no ROE for this year, and Tenet does not compute one yet
Operating margin
—
no operating margin on file
Net margin
—
no net margin on file
Current ratio
—
no current ratio on file
Net debt / EBITDA
—
no leverage ratio on file
EPS CAGR 5y
—
needs five years of positive earnings
Market cap
$237.2M
small cap
Div yield
—
no yield on file
52-wk range
13.50 – 39.60
low → high, since listing

Market cap: share price × the latest quarter's diluted weighted-average share count (vendor).

The rest of this report

Which sections of this report have data for this listing, and a live peek at each.
About Scribe Therapeutics, Inc.

We are a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention. While current genetic medicines are largely limited to r…

Not investment advice.

ETF exposure

held by 30 US ETFs · top wrappers by weightSee all ETFs holding SCTX →

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.